Answers are grounded in this paper and cite their sources.
Analysis reveals hepatocellular carcinoma patients with NASH have worse outcomes and a specific metabolomic profile, suggesting glutamine as a potential biomarker.
NASH patients are more prone to HBV reactivation following liver transplantation for HCC and exhibit worse recurrence-free survival. Glutamine may serve as a potential therapeutic target or predictive biomarker for HBV reactivation.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: